Physician profile
David V Eastham
NPI 1356412050
$303.42
in general payments reported to CMS, 2019-2025
12 companies · $50.08 in 2025
The $50.08 reported for 2025 was less than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $146 · 2020: $24.49 · 2021: $24.02 · 2022: $25.14 · 2024: $33.84 · 2025: $50.08.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $83.92.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $83.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $73.18 | 2019-2021 | |
| Ipsen Biopharmaceuticals, INC | $39.46 | 2020-2024 | Onivyde |
| Blue Earth Diagnostics | $36.25 | 2019 | |
| Genentech USA, INC. | $27.78 | 2025 | Venclexta |
| Novartis Pharmaceuticals Corporation | $22.30 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $19.19 | 2019 | |
| Boston Scientific Corporation | $18.87 | 2024 | |
| Merck Sharp & Dohme LLC | $16.81 | 2019 | |
| Amag Pharmaceuticals, INC. | $12.80 | 2019 | |
| Siemens Medical Solutions USA, INC. | $12.64 | 2022 | |
| Incyte Corporation | $12.50 | 2022 | |
| Novocure INC. | $11.64 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Eastham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.